Back to Browse Journals » Transplant Research and Risk Management » Volume 1 » Default

Managing hepatitis C in liver transplant patients with recurrent infection

Authors Tim Zimmermann, Gerd Otto, Marcus Schuchmann

Published Date September 2009 Volume 2009:1(Default) Pages 1—14


Published 13 September 2009

Tim Zimmermann1, Gerd Otto2, Marcus Schuchmann1

1Department of Internal Medicine, 2Transplantation Surgery, University of Mainz, Germany

Abstract: Hepatitis C virus (HCV) reinfection after liver transplantation (LT) and recurrent hepatitis C often lead to recurrent cirrhosis (RC). RC is one of the most frequent complications resulting in organ failure and early death after LT in HCV-positive patients with reported 5-year rates from 20% to 40%. As HCV-cirrhosis is one of the leading indications for LT, the therapeutic management is a central issue. To date, the best available therapy is a combination of pegylated interferon + ribavirin in patients with established recurrent hepatitis C proven by liver biopsy. Although increasing experience in using interferon therapy after LT has suggested better response rates, treatment is limited by a poor tolerability and high rates of severe side effects, necessitating lower doses or withdrawal of therapy. The extent to which dose reductions and the concomitant administration of growth factors affect virological response or prevent complications is still to be determined. Prospective clinical trials are mandatory to identify the best time point and schedule of antiviral treatment in transplant patients. Currently, therapeutic options need to be discussed for each individual patient. Therefore therapy should be carried out only in transplant centers with experience in managing hepatitis C after LT.

Keywords: hepatitis C, liver transplantation, recurrent infection, treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Lung transplantation for chronic obstructive pulmonary disease

Liou TG, Raman SM, Cahill BC

Transplant Research and Risk Management 2013, 5:1-20

Published Date: 4 July 2013

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P

Therapeutics and Clinical Risk Management 2012, 8:295-306

Published Date: 19 June 2012

Knowledge of adverse drug reaction reporting in first year postgraduate doctors in a medical college

Upadhyaya P, Seth V, Moghe VV, Sharma M, Ahmed M

Therapeutics and Clinical Risk Management 2012, 8:307-312

Published Date: 19 June 2012

Impact of everolimus: update on immunosuppressive therapy strategies and patient outcomes after renal transplantation

Helio Tedesco-Silva Jr, Claudia Rosso Felipe, Tainá Veras de Sandes Freitas, et al

Transplant Research and Risk Management 2011, 3:9-29

Published Date: 24 January 2011

Human amniotic membrane, best healing accelerator, and the choice of bone induction for vestibuloplasty technique (an animal study)

Mohammad H Samandari, Shahriar Adibi, Ahad Khoshzaban, et al

Transplant Research and Risk Management 2011, 3:1-8

Published Date: 22 December 2010

Role of tacrolimus prolonged release in the prevention of allograft rejection

Peter Abrams, Abhinav Humar, Henkie P Tan

Transplant Research and Risk Management 2010, 2:65-70

Published Date: 9 August 2010